×
Zoetis Total Assets 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis total assets for the quarter ending September 30, 2024 were
$14.357B
, a
1.78% increase
year-over-year.
Zoetis total assets for 2023 were
$14.286B
, a
4.28% decline
from 2022.
Zoetis total assets for 2022 were
$14.925B
, a
7.37% increase
from 2021.
Zoetis total assets for 2021 were
$13.9B
, a
2.14% increase
from 2020.
View More
Zoetis Total Assets 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis total assets for 2023 were
$14.286B
, a
4.28% decline
from 2022.
Zoetis total assets for 2022 were
$14.925B
, a
7.37% increase
from 2021.
Zoetis total assets for 2021 were
$13.9B
, a
2.14% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Takeda Pharmaceutical (TAK)
$43.3B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.2B
Astellas Pharma (ALPMY)
$18.2B
United Therapeutics (UTHR)
$16.1B
Summit Therapeutics (SMMT)
$14.7B
Neurocrine Biosciences (NBIX)
$12.1B
Shionogi (SGIOY)
$11.9B
Catalent (CTLT)
$10.7B
Jazz Pharmaceuticals (JAZZ)
$7.1B
Madrigal Pharmaceuticals (MDGL)
$6.9B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.7B
Ionis Pharmaceuticals (IONS)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$5.1B
PTC Therapeutics (PTCT)
$3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2.2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Evotec AG (EVO)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.8B
Xencor (XNCR)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Indivior (INDV)
$1.4B
Harrow (HROW)
$1.4B
Ocular Therapeutix (OCUL)
$1.4B